NCT02213367View on ClinicalTrials.gov

Bilastine Updosing in Chronic Spontaneous Urticaria

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Chronic Urticaria
Interventions
DRUG

Bilastine

20mg (8 weeks)

DRUG

Bilastine

40mg

DRUG

Bilastin

80mg

Trial Locations (1)

10117

Dpt. of Dermatology and Allergy, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT02213367 - Bilastine Updosing in Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter